Skip to main content
. Author manuscript; available in PMC: 2019 Jun 6.
Published in final edited form as: J Pharm Sci. 2018 Aug 16;107(12):3153–3162. doi: 10.1016/j.xphs.2018.07.032

Table 1.

Characterization of Current ATV-RTV-TFV DcNP and Previously Published TLC-ART 101

Formulation Protease Inhibitors Reverse
 Transcriptase
ATV-RTV-TFVa ATV RTV TFV (PMPA)
 Molar ratio relative to RTV 2 1 3
 % Association to DcNP 99 ± 8 92 ± 7 10 ± 1
TLC-ART 101b Lopinavir RTV TFV (PMPA)
 Molar ratio relative to RTV 4 1 5
 % Association to DcNP 92 ± 6 91 ± 7 10 ± 3

PMPA, 9-(2-Phosphonyl-methoxypropyly)adenine.

a

ATV-RTV-TFV DcNP was prepared accordingly to TLC-ART platform with DSPC-DSPE-mPEG2000 (9:1).9

b

From previous study.4